Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | CEL | P19835 | 2/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17318294 | 0.98 | CYP1A2 (0.46) | NOS3NOS1NOS2CYP1A2ALDH1A1 | |
| SCHEMBL11048308 | 0.93 | SIGMAR1 (0.43) | NOS3NOS1NOS2CYP1A2ALDH1A1 | |
| SCHEMBL11527036 | 0.86 | NOS3 (0.50) | NOS3NOS1NOS2CYP1A2ALDH1A1 | |
| SCHEMBL3962160 | 0.84 | NOS3 (0.49) | NOS3NOS1NOS2CYP1A2ALDH1A1 | |
| SCHEMBL8201975 | 0.81 | — | — | |
| SCHEMBL11530187 | 0.75 | — | — | |
| SCHEMBL9218437 | 0.75 | NOS3 (0.42) | NOS3NOS1NOS2CYP1A2SIGMAR1 | |
| SCHEMBL18811760 | 0.75 | NOS3 (0.42) | NOS3NOS1NOS2CYP1A2ALDH1A1 | |
| SCHEMBL324846 | 0.71 | SIGMAR1 (0.65) | CYP1A2SIGMAR1CELEPHX1 | |
| SCHEMBL9452653 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10987322-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20170112785-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2017-04-27 | — | — | US | disclosed |
| EP-3151820-A1 | IMMUNOREGULATORY AGENTS | Flexus Biosciences, Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015188085-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112785-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | NOS3 108/4885NOS1 146/4885NOS2 89/4885 |
| US-10987322-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | NOS3 108/4885NOS1 146/4885NOS2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.